Xanne Hoyt-Miggelbrink

Journal Article Vaccines (Basel) · November 30, 2025 High-grade gliomas (HGGs) and diffuse midline gliomas (DMGs) in pediatric patients carry a poor prognosis, necessitating the rapid development of novel therapies. Peptide vaccines represent a safe, repeatable, and rational immunotherapeutic modality aimed ... Full text Link to item Cite

Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.

Journal Article Clin Cancer Res · November 21, 2025 PURPOSE: Exhaustion represents a collection of programmed T cell differentiation states and an important mode of T cell dysfunction. T cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor TOX. ... Full text Link to item Cite

CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.

Journal Article Nat Cancer · September 2023 The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, ... Full text Link to item Cite

View All Publications

External Links

ORCID

Xanne Hoyt-Miggelbrink

Overview

Current Appointments & Affiliations

Recent Publications

Peptide Vaccines for Pediatric High-Grade Glioma and Diffuse Midline Glioma: Current Progress and Future Perspectives.

Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.

CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.

Recent Grants

Nervous system control and regulation of the immune system following neurological insults

Removing Barriers to Immunotherapy Against Tumors Within the Intracranial Compartment

Development of BARR2 Small Molecule Inhibitors for Brain Cancer Therapy

External Links